Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Transform Wealth LLC

Transform Wealth LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 97.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 291 shares of the biopharmaceutical company’s stock after selling 9,438 shares during the period. Transform Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $207,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mizuho Securities USA LLC lifted its stake in Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after buying an additional 3,231 shares in the last quarter. Catalytic Wealth RIA LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $1,334,000. Finally, Daiwa Securities Group Inc. grew its holdings in Regeneron Pharmaceuticals by 12.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock valued at $21,428,000 after buying an additional 2,234 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ REGN opened at $687.80 on Wednesday. The stock has a market cap of $75.58 billion, a P/E ratio of 17.02, a PEG ratio of 1.61 and a beta of 0.10. The business’s fifty day simple moving average is $735.72 and its 200-day simple moving average is $946.39. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Analysts Set New Price Targets

Several research firms have recently commented on REGN. Oppenheimer reduced their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.